Scoop: Rakuten Medical targets year-end close for $100M+ Series E to fund photoimmunotherapy pipeline: #Jefferies23
Rakuten Medical is aiming to close its Series E raise before the end of the year, with the funds designed to add fuel to its photoimmunotherapy clinical trials. As of this week, the company has docketed $107-108 million, Endpoints News has learned.
“The market situation is really tough but we are in good shape,” co-CEO and president Takashi Toraishi told Endpoints on the sidelines of the Jefferies healthcare meeting Wednesday. Since the fundraise is still ongoing, Toraishi declined to disclose the exact target size of the raise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.